Biogen Receives Dual Boost for Alzheimer’s Treatment Strategy
17.11.2025 - 07:55:04 | boerse-global.de
Biogen has secured two significant advancements that could reinvigorate the biotechnology company’s growth trajectory. Recent developments include a streamlined treatment approval in the United Kingdom for its Alzheimer’s therapy and a strategic acquisition, both strengthening the company’s neuroscience portfolio.
The company’s acquisition of Alcyone Therapeutics represents a substantial enhancement to Biogen’s neurological treatment capabilities. Central to this move is the ThecaFlex DRx
System, an implantable device that could transform administration methods for medications like SPINRAZA, used in spinal muscular atrophy treatment. This technology enables chronic intrathecal Read more...
en | US09062X1037 | BIOGEN | boerse | 68364437 |
